Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frexalimab versus tacrolimus after first kidney transplantation
MOH_2026-02-17_015664Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Feb 2026
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of frexalimab and tacrolimus in chronic kidney disease (CKD), sponsored by Sanofi. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
frexalimabtacrolimus
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on MOH_2026-02-17_015664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-02-17_015664.